The physiological and pathophysiological relevance of glucagon-like-peptide-1 receptor biased agonism

胰高血糖素样肽-1受体是治疗2型糖尿病和肥胖的主要药物靶点。作用于该受体的不同药物能够产生不同的生理输出，但缺乏对提供最佳临床效果的受体反应概况的详细了解。该项目解决了这一关键的知识差距，并将导致改进筛选和开发新的更好的药物的战略。

The glucagon-like peptide-1 receptor is a major drug target for treatment of type 2 diabetes and obesity. Different drugs acting at this receptor are capable of producing distinct physiological outputs, but a detailed understanding of the profile of receptor response that provides optimal clinical effectiveness is lacking. This project addresses this critical knowledge gap and will lead to improved for strategies to screen and develop new and better medicines.